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Objective: The objective of this selective EBM review is to determine whether or not 
administration of 800 mg IV ibuprofen reduces post-surgical pain within 24-28 hours. 
 
Study Design: A systematic review of three randomized, double blind, placebo-controlled 
studies.  
 
Data Sources: All studies were published in English during or after the year 2010. All articles 
were obtained from peer reviewed journals and databases using PubMed and CINAHL Plus. 
Selection was determined based on the relevance to the clinical question. 
 
Outcomes Measured: All three studies aimed to measure the efficacy of IV ibuprofen on the 
reduction of post-operative pain at rest and with movement by 24-28 hours. This was done using 
a visual analog scale (VAS), area under the curve (AUC), and mean difference between groups.  
 
Results: In the randomized control trial (RCT) performed by Singla et al. there was a significant 
difference (p-value <0.001) in post-operative pain reduction between the experimental and 
control group. There was a least square mean difference calculated as -269 at rest and -321.1 
with movement. Kayhan et al. performed a RCT that found a statistically significant decrease in 
pain reduction between the experimental and control groups (p-value < 0.001). A mean 
difference of -4.01 at rest and -10.22 with movement was calculated between groups. The RCT 
performed by Martinez et al. determined there to be a statistically significant decrease in pain 
between the experimental and control group. There was a mean difference of 0.08 at rest and 
0.24 with movement. 
 
Conclusion: All three studies demonstrated that 800 mg IV ibuprofen provides a statistically 
significant decrease in severity of post-surgical pain within 24-28 hours. 
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Introduction 
Ibuprofen is a non-steroidal anti-inflammatory drug, NSAID, currently used as an 
“everyday” reliever for a range of pains including muscle aches, arthritis, headaches, menstrual 
cramps, and dental pain. It is a non-selective inhibitor of the COX-1 and COX-2 enzyme that 
promotes the sensitization of pain and decreases inflammation1. Alternatively, opioids such as 
morphine are used for post-surgical pain management and provide no benefit to the underlying 
disease process. Therefore, using NSAIDs as adjunctive therapy for post-surgical pain 
management may help to promote resolution of inflammation, pain, and overall post-surgical 
healing.1  
In 2017, an opioid epidemic was classified by the U.S Department of Health & Human 
Services as a public health emergency. Research shows that there were 47,000 deaths in 2018 
secondary to prescription opioids. Of these, 32% involved prescription medications of the 
individual.2 Although opioid analgesics are the basis of care for post-operative patients, they are 
being over-prescribed, have the potential for misuse, and can lead to severe adverse reactions.1 
Adjunctive medications including ibuprofen can be used to lessen the side effects and help 
decrease the total dose of opioids required.  
Surgical care is a highly demanded specialty requiring around the clock care and medical 
attention. There are 51 million inpatient surgeries requiring opioid analgesia in the U.S. every 
year.3 In the U.S., more than 60% of patients who experienced moderate-severe post-surgical 
pain received morphine as the treatment of choice.4 The U.S. typically spends $560-$635 billion 
annually trying to treat pain, with a majority of patients requiring in-patient post-surgical care.5 
Current studies lack information comparing the cost comparison of IV ibuprofen versus the 
current mainstay of opioid analgesia post-operatively. Typically, the cost of IV ibuprofen 10 
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mg/ml is $876 for 6 mL.6 More information needs to be provided about standard cost of IV 
ibuprofen treatment in the inpatient setting.  
Studies are currently looking at the efficacy and safety of the use of IV ibuprofen in acute 
post-surgical cases. Overall data suggests similar safety profiles between IV and oral ibuprofen. 
What is unknown is how IV administration would be tolerated in prolonged therapies.1 Research 
is looking into the efficacy of a multimodal approach to post-operative pain to achieve pain relief 
while decreasing and minimizing the total amount of opioids required. This systematic review 
aims to determine if IV ibuprofen can be an efficient medication to be used in the post-surgical 
setting for pain management.  
Objective 
The objective of this selective EBM review is determining whether or not administration 
of 800 mg IV ibuprofen reduces post-surgical pain within 24-28 hours.    
Methods 
Three randomized, placebo-controlled double-blind studies from peer-reviewed journals 
were selected for this review. The studies in this review were searched, by myself, using PubMed 
and CINAHL databases with the keywords “intravenous”, “ibuprofen”, “postoperative”, and 
“pain”. Studies were selected for the review based on relevance to the clinical question, if the 
results were measured by Patient-Oriented Evidence that Matters (POEMs) and if they met the 
inclusion criteria for the review. Inclusion criteria that were required included randomized 
control trial published during or after 2010, adult patients, English language, and primary 
research. Exclusion criteria consisted of studies published before 2010 and patients under the age 
of 18 years old. A summary of the criteria for each study can be further reviewed in Table 1.  
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In all three studies, the population being reviewed are patients 18 years or older 
undergoing elective surgical care, requiring hospitalization and need for IV pain management. 
All three studies evaluated the use of 800 mg IV ibuprofen, with rescue IV morphine, as a post-
surgical analgesia intervention. In two of the articles, the use of IV ibuprofen was compared to 
the use of IV saline. In the third study, IV acetaminophen was used as the control group. 
Differences in medication administration are highlighted in Table 1, as timing of infusions 
varied. These studies used a visual analog scale (VAS) to gather information from patients on 
pain level. To evaluate efficacy of IV ibuprofen on reduction of post-surgical pain by 24-28 




The outcome measured in all three studies looked at the efficacy of IV ibuprofen and 
whether or not it can reduce post-surgical pain. The data was collected by VAS to assess pain at 
selected hourly intervals at rest and with movement. The VAS was a self-assessment that ranked 
pain from 0 to 100 (0= no pain and 100= the worst pain imaginable).4,7 The scale is a continuous 
line from 0-100 without intermediate descriptors to avoid unclear responses. At each time check, 
the patient would mark a line on the VAS to indicate their pain at that time period. In the study 
by Martinez et al. the VAS was on a 0-10 scale instead, but instructions were the same for 
participants.8 For the purpose of this review, a common time interval of 24-28 hours was used to 
compare pain levels. In order for the patients to participate in the VAS, they were required to be 
coherent and able to comply to study procedures after recovery from sedation. To analyze the 
data and qualify the outcomes, the studies used mean difference between groups, AUC and p-
values to determine the significance.4,7
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Results 
 
Singla et al. conducted a randomized double-blind placebo-controlled trial to determine if 
administration of IV ibuprofen can significantly decrease pain for adult patients undergoing 
orthopedic surgical procedures. The study was conducted at eight hospitals in the U.S and South 
Africa. Patients ages 18 to 80 scheduled to have orthopedic surgery requiring a hospital stay and 
need for morphine analgesia for at least 28 hours were considered for the study.4 Further 
inclusion and exclusion requirements are located in Table 1. A total of 185 patients were 
randomized to receive either 800 mg IV-ibuprofen (N=99) or the placebo (N= 86) every six 
hours, with the first dose administered pre-operatively at the induction of anesthesia. The 
remainder of the doses were scheduled every 6 hours for the next 24 hours. All patients had 
access to IV morphine for rescue analgesia. VAS was used as a self -assessment of pain at rest 
(VASR) and movement (VASM) from hour 6-28 (post-operative period) after receiving the first 
dose at the induction of anesthesia.4 This self-assessment was collected from hour 6-28 at 6-hour 
intervals. VAS was a standard 100-mm scale. Efficacy was measured using AUC from 6 to 28 
hours for the VAS assessment with rest and movement (Table 2).4 P-value and least squares (LS) 
means difference (95% CI) was calculated from analysis of covariance (ANCOVA) model 
(Table 3). 4 Statistical analysis determined there to be a significant decrease in pain of the 
experimental group compared to the control group.  
Table 2. VAS Mean Scores Expressed as AUC (standard deviation) with Movement and Rest 
from Hours 6-284  
 Experimental Control Group 
Pain at Rest 
(6-28 hours) 620.8 (401.0) 910.9 (424.3)  
Pain with Movement  
(6-28 hours) 970.1 (422.2) 1,307.8 (388.7) 
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Table 3. Change in Pain Level Expressed as LS Means Difference (95% CI) Between 
Experimental and Control Group4 
 Mean Difference P-Value 
Pain at Rest -269.0 (-386.8, -151.2) *<0.001 
Pain with 
Movement -321.1 (-436.7, -205.4) 
*<0.001 
*=Statistically Significant (P<0.05) 
 
Kayhan et al. conducted a randomized double-blind placebo-controlled study comparing 
the use of IV ibuprofen to IV acetaminophen. There were 80 subjects aged 18-65 (ASA physical 
status II-III) undergoing laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric 
bypass surgery that participated in the study at a university hospital.7 There were five subjects 
lost to follow-up in the control group; four subjects secondary to protocol violations and one 
secondary to allergic reaction. One patient was excluded from the analysis of the experimental 
group secondary to post-operative complications. These patients were randomly selected to 
receive 800 mg IV ibuprofen (N=35) or the control 1 g IV acetaminophen (N=39) every 6 hours 
for the first 24 hours following surgery.7 In addition, patient-controlled analgesia with morphine 
was administered if VAS was ≥ 40 when patients completed the VAS at the pre-determined time 
intervals.7 At these pre-determined intervals every 6 hours, the patient would complete a VAS 
(0= no pain to 100= the worst pain imaginable) to qualify pain.7 Patients were told to assess their 
pain at rest (sitting position) and with movement (standing from a sitting position) every 6 hours. 
To determine overall pain at the various time points, the AUC was analyzed over the first 24 
hours to provide mean VAS scores for both the experimental and control groups with rest and 
movement (Table 4).7 Quantitative data was calculated using least squares mean difference with 
95% confidence interval. In addition, the Analysis of Variance (ANOVA) with Bonferroni 
multiple comparisons test determined that there was a significant difference between the pain 
reduction of the experimental and control groups (Table 5).7  
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Table 4. VAS Scores Expressed as Mean ± SD (Standard Deviation) Over a 24-Hour Period at 
Rest and With Movement7 
 Experimental Control Group 
Pain at Rest 
(1-24 hours) 
28.73 ±19.53 32.34 ± 22.43 
Pain with Movement  
(1-24 hours) 35.53±20.22 43.20±22.23 
 
Table 5. Change in Pain Level Measured as Mean Difference Between Experimental and 
Control Groups7 
 Mean Difference P-Value 
Pain at Rest -4.01 (-6.17, -1.84) *<0.001 
Pain with Movement -10.22 (-12.53, -7.92) *<0.001 
*=Statistically Significant (P<0.05) 
 
Martinez et al. conducted a randomized control trial designed to evaluate the efficacy of 
IV-ibuprofen for the treatment of pain in post-operative elective abdominal and orthopedic 
surgery in adult patients.8 The study was conducted at a total of nine Spanish hospitals in the 
inpatient setting. Further discussion of inclusion and exclusion criteria are in Table 1. There were 
206 patients assigned to receive either 800 mg IV ibuprofen or a placebo every 6 hours. All 
patients had access to morphine through a patient controlled analgesic pump. Ultimately, the 
analysis was limited to abdominal surgeries due to limited orthopedic enrollment. Therefore, the 
experimental group (N=72) and placebo group (N=63) all underwent abdominal surgery.8 The 
first dose of the study drug was administered upon skin closure indicating “Hour 0”. Subsequent 
doses were administered every 6 hours for a total of 24 hours. All patients had access to a 1 mg 
bolus dose of IV morphine, if desired, upon discharge from the operating room. Subsequent 
dosing would only be permitted by the patient’s physician if adequate pain control was not 
achieved. VAS was performed at each six-hour interval over the 24-hour period and reported as 
mean ± standard error of the mean (SEM; Table 6).8 Mean difference was used to analyze the 
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difference in pain levels between groups (Table 7). Statistical significance calculated with the 
Log-Rank test found a larger decrease in pain level in the experimental versus control group.8  
Table 6. VAS Scores Expressed as Mean ± SEM Over 24-Hour Period at Rest and With 
Movement8 
 Experimental Control Group 
 Hour 0 Hour 24 Hour 0 Hour 24 




4.32±0.36 1.90±0.30 5.56±0.42 3.38±0.44 
 
Table 7. Change in Pain Level Measured as Mean Difference Between Experimental and 
Control Groups8 
 Mean Difference P-Value 
Pain at Rest 0.08 *<0.001 
Pain with 
Movement 0.24 *<0.001 




Opioid medications continue to be the mainstay of treatment for post-surgical pain. Due 
to the recent opioid epidemic, more research has been conducted in effort to use adjuvant 
medication in post-surgical analgesia to reduce levels of morphine consumption. Caldolor, an 
intravenous form of ibuprofen was first approved on June 11, 2009 for the adult population and 
November 20, 2015 for the pediatric population.9 According to the Food and Drug 
Administration (FDA), NSAIDS and specifically Caldolor, have a serious risk of cardiovascular 
and gastrointestinal events.10 Furthermore, it is contraindicated in the setting of peri-operative 
pain for coronary bypass graft surgery. Additionally, NSAIDs may also diminish the effects of 
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ACE- inhibitors. Adverse reactions may include nausea, flatulence, vomiting, headache, 
hemorrhage, and dizziness.10 Opioids also offer their share of adverse effects including 
respiratory depression, sedation, allergic reactions, and gastrointestinal effects.1 Despite the 
potential for adverse effects, oral ibuprofen is a trusted anti-inflammatory and analgesic 
medication. Until recently, ibuprofen has not been considered in the inpatient setting due to lack 
of available parenteral formulation and difficulty for IV production due to its lipophilic 
properties.1 With an FDA approved intravenous formulation, research is looking at its use in 
reduction of post-surgical pain. This is due to the mechanism of action working peripherally and 
centrally to reduce pain and inflammation, whereas morphine reduces pain but has no 
improvement to the underlying disease process.1 
All three studies looked to answer the question if the use of IV ibuprofen can be used to 
reduce post-surgical pain. In the study by Kayhan et al. there was a statistically significant 
decrease in pain with IV ibuprofen as confirmed with p-value (p <0.001).7 With a mean change 
of 4 at rest and 10 with movement, a patient could feel a significance in pain reduction. In 
Martinez et al. there was a statistically significant change in pain reduction between both 
experimental and control groups as determined by the p value (p<0.001).8 Based on patient 
concern, a change of 0.08 at rest and 0.24 with movement would not produce a noticeable 
change on a 10 cm VAS scale. In addition, Singla et al. also found a statistically significant 
decrease in pain with the experimental group, confirmed by p-value. There was a 25% decrease 
in the mean AUC-VASM and a 31.8% decrease in the mean AUC-VASR.4 In regard to the 
patient, a decrease this level would be noticed by a patient.  
In regard to limitations, there are a few concerns to address with the studies. First, there 
was a difference in the VAS scales and analysis between trials. Being able to compare a VAS of 
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the same numerical length would have allowed for more efficient comparison. Having a larger 
scale (0-100) could have allowed the patient to report a larger change in pain scale compared to 
someone limited to a smaller scale (0-10). In addition, Martinez et al. excluded the entire 
orthopedic group from the efficacy analysis due to reduced sample size. This impacted the 
overall VAS mean resulting in lower values and, ultimately, a smaller difference between 
means.8 Orthopedic surgery is reported to produce some of the highest ranked post-surgical pain, 
which would have been beneficial to the generalizability of the study.8 In combination, these 
three articles studied participants of abdominal and orthopedic surgeries. Although these are 
some of the most common procedures, these articles lack a variety of surgical specialties that 
also require post-surgical care.  
This review, in particular, limits the discussion of IV Ibuprofen’s safety profile. The 
safety profile is outside the scope of the review, but it would be beneficial to inform the audience 
on the drug’s side effects. Drug reactions may influence how the patient rates their pain or it may 
result in participants withdrawing from the study. Additionally, this review does not focus on the 
amount of morphine that was used. The review is patient oriented and only focuses on the effects 
of IV Ibuprofen. It does not focus on statistical changes with the overall amount of morphine to 
determine if there was a statistically significant reduction.  
Conclusions 
 
In summary, the use of 800 mg IV-ibuprofen reduces post-surgical pain within 24-28 
hours. All three studies showed a statistically significant reduction in post-surgical pain with the 
experimental group compared to the placebo group. Although statistically significant, Martinez 
et al. provided a decrease that would likely be undetected by a patient. This value was presumed 
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to be due to the large exclusion of an entire category of participants.8 With the strength of the 
additional studies, it provides a clearer answer to the proposed efficacy of IV ibuprofen.  
Future studies should try to increase generalizability by studying a variety of surgical 
specialties, as well as the use of pediatric patients. To add, more research needs to be done to 
evaluate the cost of IV Ibuprofen and if this form of pain management will be cost effective. 
Such a large difference in cost compared to the mainstay treatment will deter health professionals 
and insurance companies from using IV Ibuprofen to treat post-operative pain. Therefore, more 
research needs to be conducted to lower the cost of the drug to be beneficial to the patient and 
payers. Additionally, research should be done to analyze the reduction of morphine use found 
within these studies and those to come. Although not a direct patient-oriented concern, opioids 
do have the risk of causing adverse effects on patients and dependency.1 Future review may 
show a statistically significant decrease in amount of morphine used with the addition of 
adjuvant IV ibuprofen. In this case it will help to strengthen the argument that IV-ibuprofen 
should be used in post-surgical analgesia care. In sum, 800 mg IV-ibuprofen should be 
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